Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition-Reference-Cited by-同舟云学术

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

Published:2014-08-01 Issue:4 Volume:45 Page:1430-1436
ISSN:1019-6439
Container-title:International Journal of Oncology
language:en
Short-container-title:

Author:

KOGITA AKIHIRO,TOGASHI YOSUKE,HAYASHI HIDETOSHI,SOGABE SHUNSUKE,TERASHIMA MASATO,DE VELASCO MARCO A.,SAKAI KAZUKO,FUJITA YOSHIHIKO,TOMIDA SHUTA,TAKEYAMA YOSHIFUMI,OKUNO KIYOTAKA,NAKAGAWA KAZUHIKO,NISHIO KAZUTO

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L);Therapeutic Advances in Medical Oncology;2024-01

2. Punicalagin as a Promising Therapeutic Agent in Hepatocellular Carcinoma: Comprehensive Bioinformatic and Experimental Analysis of Metastasis Modulation in Hepg2 Cells;2024

3. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms;Frontiers in Pharmacology;2023-10-25

4. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries;Molecular Oncology;2023-05-15

5. Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease;Translational Lung Cancer Research;2023-02